BROSSARD, QUEBEC--(Marketwired - March 11, 2014) - Diagnos Inc. ("DIAGNOS" or "the Corporation") (TSX VENTURE:ADK), a leader in healthcare technical services including, screening, software and algorithm development, data analysis, and image processing, announced today a further expansion of the agreement announced on November 26th 2013 to further increase screening capacity in the country.
"Having announced a 100% expansion of our screening program in the UAE in November 2013, we are very pleased to have this further 50% expansion only 4 months later. Our client has seen a material impact on their business in the UAE and asked us for this increase to capture emerging market demand for their products and consequently for our services which are helping drive that demand. As a result of this expansion the client will now have a total of 12 screening units operating across the UAE and will be able to pursue further opportunities with key health care providers in the country. We are very happy that our service is appreciated by the client and it is demonstrating a very positive impact on their bottom line, as evidenced by subsequent expansions of the program. Due to our favourable program performance and strong client relationship, we are now pursuing materially important leads generated by our client's complimentary referrals to key country-level decision-makers worldwide within the organization." said Peter Nowacki, Diagnos' Vice-President.
About DIAGNOS
Founded in 1998, DIAGNOS is a publicly traded Canadian corporation, with a mission to commercialize technologies to improving decision making processes in different sectors. DIAGNOS offers products, services, and solutions to clients in a variety of fields including healthcare and natural resources.
About DIAGNOS Healthcare
DIAGNOS Healthcare is a business division with DIAGNOS Inc., achieving international recognition as leader in healthcare technical services including, screening, software and algorithm development, data analysis, and image processing. Through its Healthcare division, DIAGNOS offers turn-key diabetic retinopathy screening services to patients in various locations around the world.
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For further information on DIAGNOS, please visit our website at www.diagnos.com or the SEDAR website at www.sedar.com.
Contact Information:
President
DIAGNOS Inc.
(450) 678-8882 ext 224